Low-dose rapamycin and ovarian aging: first trial results show only small, untested differences
In a small randomized trial at Columbia University, 50 women aged 35 to 45 took a weekly low dose of rapamycin or a placebo for 12 weeks. A year later, a blood marker of the egg supply had fallen slightly less in the rapamycin group, but the posted results include no statistical test, and other measures did not line up. Registry results, not a peer-reviewed paper.
Can a drug slow the aging of the ovaries? A team at Columbia University tested this with rapamycin, a drug that extends lifespan in mice and other animals, and has now posted the results of its pilot trial in women. The short answer: the differences between the rapamycin and placebo groups were small, the team did not post any statistical test, and the results have not been through peer review. This is a first look, not a verdict.
Why the ovaries
The ovaries age faster than most of the body. According to the trial's registry entry, fertility starts to fall from around age 35 as the number and quality of eggs decline, and menopause follows at around 51. Menopause raises the risk of heart disease, bone loss and, as the entry notes, cognitive decline and dementia. And while people now live much longer, the age of menopause has barely moved.
Rapamycin blocks a protein called mTOR, which helps cells decide whether to grow or to save resources. In mice, the team and others had shown that rapamycin can delay ovarian aging. The idea is that it slows the steady "waking up" of the egg-containing follicles, so the supply lasts longer. This trial asked whether something similar shows up in women.
What they did
The trial enrolled 50 women aged 35 to 45 who still had regular periods but were in the early stage of the transition towards menopause. They either did not plan to become pregnant within the next year and a half, or had not been able to conceive because of a low egg reserve and had no healthy embryos after IVF. Half were randomly assigned to 5 mg of rapamycin once a week, a low dose, and half to a dummy pill (placebo), for 12 weeks. Neither the women nor the doctors knew who got what.
The main measure was AMH (anti-Müllerian hormone), a blood hormone made by the small follicles in the ovaries; the more follicles are left, the higher it is, and it falls with age. The team also counted follicles by ultrasound and measured two hormones of the menstrual cycle, estradiol and FSH. Everything was measured at the start and again at 12 months. All 50 women finished the study.
What they found
The posted numbers are group averages:
- AMH went from 1.18 to 1.12 ng/mL in the rapamycin group and from 1.16 to 0.97 ng/mL in the placebo group. So it fell by about 0.06 with rapamycin and about 0.19 with placebo.
- Follicle counts went the other way: from 9.04 to 8.60 with rapamycin and from 9.00 to 10.33 with placebo. The placebo figure at 12 months varied hugely between women (a standard deviation of 12.73), which suggests a few unusual values.
- Estradiol and FSH changed little in either group.
- Side effects were few. No woman had a serious adverse event. One woman on rapamycin had hives; three on placebo reported problems such as rash, swelling or bloating.
What to keep in mind
- No statistical test was posted. The registry gives averages and their spread, but no comparison between the groups. The spread is large: for AMH, the standard deviation within each group was around 0.8 ng/mL, several times bigger than the difference between the groups. On these numbers alone, nobody can say whether rapamycin did anything.
- The measures disagree. AMH looked slightly better with rapamycin, follicle counts slightly worse.
- Small and short. The registry entry calls it a pilot study: 25 women per group, treated for three months. Whether ovaries age more slowly can only really be seen over many years, for example in the age of menopause.
- Not yet a paper. These are results the team posted on ClinicalTrials.gov, the public trial registry. A peer-reviewed paper may give the full analysis.
- Rapamycin is a prescription drug. It suppresses the immune system and is used in medicine to prevent the rejection of transplanted organs; it can have serious side effects. This trial used a low dose under medical supervision, and it is not a fertility treatment.
Why it matters
Ovarian aging is one of the earliest and most noticeable kinds of aging in the human body, which makes it an attractive place to test drugs that slow aging in animals. This trial tested rapamycin for that purpose in women against a placebo. Its posted results do not show a clear effect, but they do show that a three-month course of low-dose rapamycin was taken by all 25 women without serious problems. A larger, longer trial, and a full statistical analysis of this one, would be needed before anyone can say whether rapamycin slows the ovarian clock.